The FDA has officially approved Veppanu (vepdegestrant; ARV-471), a first-in-class oral selective estrogen receptor degrader (SERD) using PROTAC technology. Developed through a partnership between Pfizer and Arvinas, the drug marks a milestone in targeted breast cancer therapy.
1. Indication and Clinical Performance
Veppanu is indicated as a once-daily treatment for adults with ER-positive, HER2-negative advanced or metastatic breast cancer who carry ESR1 mutations and have progressed following endocrine therapy.
-
Trial Outcomes: In the Phase III VERITAC-2 study, Veppanu demonstrated a median progression-free survival (PFS) of 5 months in the ESR1-mutant cohort, compared to 2.1 months for the fulvestrant control group—reflecting a 43% clinical benefit.
-
Niche Efficacy: The approval specifically focuses on the ESR1-mutated subgroup, as the drug failed to show statistically significant PFS improvement in the broader study population (ESR1 wild-type).
2. Evolving Commercial Strategy
Despite the regulatory green light, Pfizer and Arvinas have shifted their market approach:
-
Initial Investment: Pfizer paid $650 million upfront in 2021 to co-develop the therapy.
-
External Partnership: Following the mixed results across the entire study population, the partners announced last September that they would seek a third-party commercial partner rather than selling the drug themselves. Arvinas subsequently adjusted its workforce to align with this strategic pivot.
3. A Competitive Landscape
Veppanu enters a highly competitive market for oral therapies targeting the ESR1-mutant subtype:
-
Stemline’s Orserdu (elacestrant): Approved in 2023, it demonstrated a 45% reduction in the risk of progression or death.
-
Eli Lilly’s Inluriyo (imlunestrant): Recently cleared by the FDA after showing a 38% risk reduction in the EMBER-3 trial.
-
Roche’s Giredestrant: A promising candidate following success in multiple Phase III trials.
-
AstraZeneca’s Camizestrant: Faced a recent setback as an FDA advisory panel voted against its approval based on its latest clinical data submission.
The approval of Veppanu adds a vital new tool for precision oncology, allowing healthcare providers to tailor treatments based on genetic biomarkers while showcasing the power of protein degradation in modern medicine.